To the best of our knowledge, this is the first study showing that the expression of DDB1 and CUL4A assessed by routine, diagnostic IHC evaluation of bone marrow samples is associated with the outcome of multiple myeloma patients treated with IMiDs. This evidence concerns the gene CUL4A and plasma cell myeloma.